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Abstract
Background—Thyroid cancer incidence is increasing worldwide. Incorporating 22 years of
incidence data through 2009, we extend examination of these trends among a wide array of
subgroups defined by patient (age, sex, race/ethnicity, and nativity), tumor (tumor size and stage),
and neighborhood (socioeconomic status and residence in ethnic enclaves) characteristics, to
identify possible reasons for this increase.
Methods—Thyroid cancer incidence data on 10,940 men and 35,147 women were obtained from
the California Cancer Registry for 1988–2009. Population data were obtained from the 1990 and
2000 US Census. Incidence rates and 95% confidence intervals (CI) were calculated and incidence
trends evaluated using Joinpoint regression to evaluate the timing and magnitude of change
(annual percent change (APC) and rate ratios).
Results—The incidence of papillary thyroid cancer continues to increase in both men (APC=5.4,
95% CI: 4.5–6.3 for 1998–2009) and women (APC=3.8, 95% CI: 3.4–4.2 for 1998–2001 and
APC=6.3, 95% CI: 5.7–6.9 for 2001–2009). Increasing incidence was observed in all subgroups
examined.
Conclusions—While some variation in the magnitude or temporality of the increase in thyroid
cancer incidence exists across subgroups, the patterns (1) suggest that changes in diagnostic
technology alone do not account for the observed trends and (2) point to the importance of
modifiable behavioral, lifestyle, or environmental factors in understanding this epidemic.
Impact—Given the dramatic and continued increase in thyroid cancer incidence rates, studies
addressing the causes of these trends are critical.
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Introduction
Substantial increases in the incidence of thyroid cancer over the last 30 years have been
observed in many countries worldwide (1–5). In the US, significant increases in thyroid
cancer incidence rates began in 1980 and the rate of increase has accelerated since 1997 (6).
While thyroid cancer is three times more common in women than men, the rate and
temporality of this increase is similar in men and women (6). In addition, the increase
appears to be largely limited to papillary thyroid cancer (4, 5, 7–10) and most prominent
among small tumors <1 cm (7, 8, 11). While some authors have attributed this increase
solely to improvements in diagnostic technology and imaging (7, 12–14) leading to the over-
diagnosis of occult tumors (14, 15), most have concluded that other factors are also involved
(2, 3, 8, 10, 11, 14, 16–22).
Here we present a comprehensive evaluation of temporal trends in thyroid cancer incidence
by patient, tumor, and selected neighborhood/contextual factors in the diverse California
population. This work extends previous analyses which have examined trends in other
populations through 2005, by several calendar years, to 2009, thus, evaluating current
trends. In addition, it expands the scope of previous work by evaluating variation in thyroid
cancer incidence by previously unexamined individual-level (i.e., nativity) and contextual-
level (i.e., residence in an ethnic enclave among Hispanics and Asian/Pacific Islanders
(APIs)) factors which reflect degree of acculturation (23). The contextual-level acculturation
variable has, to our knowledge, only been compiled for census-regions within California, as
has denominator data specific to the joint distribution of age, ethnicity, and nativity which is
necessary for computing nativity-specific rates and evaluating trends by our individual-level
acculturation measure. Since acculturation has been found to modify the predictive nature of
socioeconomic status (SES) in other cancer studies (24), the evaluation of California data in
this regard may provide additional insight into what is known about thyroid cancer trends.
Finally, we address the impact that improved completeness of tumor size data has on the
observed trends.
Materials and Methods
Cancer incidence data were obtained from the California Cancer Registry (CCR), which is
part of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER)
Program. Reporting of cancer cases to the CCR is mandated by law, and data quality,
completeness, and timeliness of reporting meet SEER standards (25). Cases were included
in the present analysis if they were residents of California when diagnosed with a first
primary invasive thyroid cancer (International Classification of Diseases for Oncology
version 3 [ICD-O-3] site code C73.9) between January 1, 1988 and December 31, 2009.
Primary analyses focused on papillary thyroid carcinoma including its follicular variant
(ICD-O-3 histology codes 8050, 8260, 8340–8344 and 8350).
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For each cancer case, we obtained the following information from the CCR: age at
diagnosis, date of diagnosis, sex, race/ethnicity, birthplace (when available), census tract of
residence at diagnosis, tumor size, and stage at diagnosis. These data are routinely abstracted
from the medical record. The North American Association of Central Cancer Registries
(NAACCR) Hispanic and Asian Pacific Islander Identification Algorithms (NHIA and
NAPIIA, respectively), which are based on surname, maiden name, and birthplace, were
used to improve classification of Hispanic and specific API ethnicities (26, 27). Birthplace/
nativity data were augmented as described below. Census tract of residence was used to
determine neighborhood SES. For Hispanics and APIs, residence in an ethnic enclave, was
determined as described below. Disease stage was classified according to the SEER
classification system as localized, regional, distant, or unknown. The SEER staging system
for papillary thyroid cancer (and its follicular variant) is independent of tumor size. Local
refers to a tumor confined to the thyroid gland. Regional indicates spread to the lymph nodes
or extranodal tissue in the neck. Distant refers to metastatic spread elsewhere in the body.
General population data was obtained from the 1990 and 2000 Census Summary File 3
(SF-3). Population counts by sex, race/ethnicity, and five-year age group for California were
used. For nativity-specific population estimates, data from the 1990 and 2000 Census’s 5%
Integrated Public-Use Microdata Sample was used to estimate age- and nativity-specific
population counts for each ethnic group by smoothing with a spline-based function (28, 29).
For intercensal years, the foreign-born population was estimated using cohort component
interpolation and extrapolation methods, adjusting the estimates to the age and year
populations provided by the California Department of Finance for years 1988–1989 and by
the National Center for Health Statistics for years 1990–2004. At the time of analysis, 2010
Census data by nativity were not yet available and extrapolation of nativity-stratified
population estimates beyond 2004 would have resulted in unstable estimates..
Analyses by Nativity
Information on birthplace is routinely collected by the CCR from hospital medical records
and augmented with data from death certificates. Our prior research shows that these data,
when available, are highly accurate at the level of US- and foreign-born (30, 31). However,
they are missing on approximately 30% to 35% of Hispanic and API cases. As described
previously, we have developed an optimized system for imputing birthplace with minimal
bias using the first five digits of the Social Security number, which correspond to the state
and year of issuance (24, 32, 33).
Analyses by Neighborhood Characteristics
A neighborhood SES quintile was assigned to each person based on their census tract of
residence at the time of diagnosis and a previously developed index that incorporates Census
data on education, income, occupation, unemployment, and housing costs (34). Census data
from 1990 was used for determining the SES index for the period 1988–1992 and 2000
Census data was used for the period between 1998 and 2002. Quintiles of SES were based
on ranking all California census tracts according to this index within each time period.
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Residence in an ethnic enclave, defined as a geographic unit with a higher concentration of a
foreign-born race/ethnic-specific population and language(s) than other geographic units,
was determined for each Hispanic or API person’s census tract based on a previously
developed index that incorporates 2000 census data on race/ethnicity, nativity, immigration
history, English and native language fluency, and linguistic isolation (24, 35). The census-
tract level index is based on averaging the data at the block group level for each tract. Each
Hispanic and API person was assigned to an enclave quintile based on their census block-
group of residence at diagnosis.
Analyses of neighborhood SES and residence in an ethnic enclave were limited to persons
diagnosed in the five years around the 1990 and 2000 decennial censuses (i.e., 1988–1992
and 1998–2002).
Statistical Analyses
SEER*Stat software (36) was used to compute age-adjusted and age-specific incidence rates
per 100,000 persons, standardized to the 2000 US standard million population, and
corresponding 95% confidence intervals (CI). Incidence rate ratios (IRR) and corresponding
CIs were calculated to estimate the magnitude of the difference between incidence rates for
various time periods, with the earlier time period being the reference group. Time trends in
incidence rates between 1988 and 2009 were also examined using Joinpoint Regression (37,
38). This software calculates the annual percent change (APC) in incidence rates by fitting a
series of least squares regression lines to the natural logarithm of the age-adjusted incidence
rates (the dependent variable), using calendar year as the independent regression variable.
This method allows for the identification of all changes in the slope of the regression (trend)
line that represents statistically significant contributions to the explanatory model based on
the Permutation Test and the Bayesian Information Criterion; the points at which the trend
lines change are termed the “joinpoints.” Results from the Joinpoint analysis are presented
in Table 2 as a given number of “trends” (i.e., joinpoints) of a given magnitude (i.e., the
APC) for a group of years for each subgroup examined.
The potential impact of the set of {kij} missing or unknown tumor sizes, for years i=1988,
…, 2009 and age groups j=1, …, 18, on temporal trends in rates by tumor size was assessed
by determining how best to apportion the kij cases to the seven levels of tumor size, from
<0.1 to 5+ cm, in such a way as to minimize differences in the magnitude of temporal
trends. Specifically, a set of seven non-negative proportions (p1, p2, …, p7) that sum to 1,
corresponding to the seven levels of tumor size, was sought such that, when pkkij cases were
added to the existing case count for year I and age group j, the differences in AAPC for the
resulting rates over time among the seven tumor sizes was minimized. Constrained nonlinear
optimization was used to determine the proportions, where the criterion to be minimized was
deviance between two nested Poisson Generalized Linear Regression models with a log link.
The more general model allowed a separate slope for each tumor size, while the nested
model required a common slope among the seven tumor sizes. (Each model allowed
different intercepts for each tumor size.)
Horn-Ross et al. Page 4
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Results
Between 1988 and 2009, 10,940 men and 35,147 women were diagnosed with thyroid
cancer in California. Among men and women, 80% and 86%, respectively, of all thyroid
cancers were of papillary histology, incidence of which increased significantly during this
time period (Figure 1). Among men, no increase was observed for follicular, medullary or
anaplastic thyroid cancers; however, tumors for which histology was not specified increased
significantly (from 0.09 per 100,000 men in 1988–92 to 0.14 in 2003–2009; IRR=1.66, 95%
CI: 1.17–2.41). Among women, a significant increase was observed for follicular tumors
(IRR=1.21, 95% CI: 1.10–1.34), but not for medullary, anaplastic, or tumors of unspecified
histology. The incidence of papillary thyroid cancer increased from 1.99 to 3.31 per 100,000
men (IRR=1.66, 95% CI: 1.57–1.77) and from 5.56 to 11.37 per 100,000 women (IRR=2.04,
95% CI: 1.97–2.12) between 1988–92 and 2003–09 (Table 1). Among men, this increase
began in 1998, while among women, significant annual increases were observed during the
entire study period but accelerated as of 2001 (APC1998–2001=3.8, 95% CI: 3.4–4.2 and
APC2001–2009=6.3, 95% CI: 5.7–6.9; Table 2).
The remainder of the analyses were limited to papillary thyroid cancer. The patterns
observed for men and women for all subgroups were generally similar. Table 1 presents the
incidence rates for the earliest (1988–1992) and latest (2003–2009) time periods examined
and the IRRs comparing rates for these two time periods stratified by several individual and
tumor characteristics. Table 2 presents temporal changes in the APC over the entire time
period studied. For women, significant increases in papillary thyroid cancer are seen across
all subgroups examined (including age, race/ethnicity, birthplace, tumor size, and stage)
with the exception of tumors of unknown size or stage, for which significant decreases are
observed. Overall, for both men and women, the magnitude of the temporal increase in rates
was greater with increasing age and slightly lower among APIs than other racial/ethnic
groups (Table 1), the latter due to the lower IRRs for foreign-born API men and women
compared to their US-born counterparts. However, during the latter part of the study period,
the rate of increase accelerated for men aged 35–49 and women aged 35–64 and white and
API men and women (Table 2). For Hispanic men and women, increases were similar
regardless of nativity, while for API men and women, the overall rate of increase was
substantially greater among those who were US-born. While we attempted to examine the
effects of nativity within the disaggregated API ethnic groups, the number of cases in many
of the cells became small and the differences were not statistically significant (data not
shown).
Tumors 1.5 cm or smaller increased at a greater rate than larger tumors, although significant
temporal increases were seen for all size tumors, including those ≥5.0 cm. Indeed, the
greatest increase in incidence occurred among the earliest stage tumors (<2 cm / local stage;
IRR=3.28, 95% CI: 3.07–3.50 for women and IRR=3.20, 95% CI: 2.76–3.73 for men) but
with a large and statistically significant increase also seen among the latest stage tumors (≥2
cm / advanced stage; IRR=2.45, 95% CI: 2.23–2.69 for women and IRR=2.13, 95% CI:
1.84–2.47 for men). There was also a significant acceleration in the rate of increase of small
but advanced tumors (<2 cm / advanced (regional or distant) stage) among women since
2005. While tumors of unknown stage account for only 2% of all papillary thyroid cancers,
Horn-Ross et al. Page 5
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2015 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
tumors of unknown size account for 10% overall, declining from 27% in 1988–92 to 5% in
2003–09. Thus, we examined whether the increase in tumors of any size might be due to the
decrease in tumors of unknown size. We found that with an optimal choice of proportions of
unknowns allocated to each of the size categories, the differences in category-specific rate
increases over time, as measured by the reduction in deviance in a model with separate
slopes compared to a model restricted to a common slope, can be reduced by approximately
90% in women, and disappear altogether in men (see Figure 2 for women). Hence, while
there does appear to be differences in the rates of increase over time across all of the size
categories, the magnitude of the rate change for specific tumor sizes may not be as dramatic
as what is depicted by analysis of the cases restricted to data with known size categories.
Table 3 presents the incidence rates by neighborhood characteristics for the two five-year
periods around the decennial censuses (1988–1992 and 1998–2002) and the IRRs comparing
rates for these two time periods. The incidence of papillary thyroid cancer increased
similarly across all levels of SES. In addition, the tumor size-specific patterns of increase
were similar for persons of low and high SES. For Hispanics, rates increased similarly
regardless of SES or residence in an ethnic enclave. For APIs, the increase in rates was
slightly, but not statistically significantly, greater among those of higher SES but did not
vary according to residence in an ethic enclave.
Discussion
During the last 20 years in California, there has been a significant, rapid, and continued
increase in thyroid cancer incidence rates in all subgroups defined by patient (age, sex, race/
ethnicity, and nativity), tumor (tumor size and stage), or contextual (SES and, among
Hispanics and APIs, residence in ethnic enclaves) characteristics. While some variation in
the magnitude or temporality of these increases exists across subgroups, these patterns
suggest that changes in diagnostic technology or surveillance patterns alone cannot account
for this epidemic. Other modifiable behavioral, lifestyle, or environmental factors are most
likely to be involved.
Prior concerns that the trends in thyroid cancer incidence were largely related to changes in
diagnostic technology were well founded. The 1980s saw substantial changes in the
technologies used to diagnose thyroid cancer: ultrasound imaging in the early part of the
decade and ultrasound-guided fine needle aspiration (FNA) in the latter part (8). These
technologies achieved widespread use by the mid-1980s and early 1990s, respectively (7).
The greater diagnostic ability of these screening technologies combined with the relatively
slow-growing nature of many thyroid cancers and the presence of “occult”
microcarcinomas, is undoubtedly responsible for a portion of the increased incidence of
thyroid cancer over time, particularly in the 1990s. Indeed, the increase in tumors <1 cm and
1.0–1.4 cm was greater than that of larger tumors. However, as observed here and elsewhere
(8, 11, 19), there has also been a statistically significant temporal increase in larger tumors,
including those >5 cm, and tumors classified as regional or distant SEER stage. But
interpretation of the trends by tumor size is complicated by the consistent improvement in
the completeness of tumor size information in cancer registry data over the course of the last
twenty years. In our sensitivity analysis, we found that optimal allocation of the tumors of
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unknown size into the specific size categories had the largest impact on the smallest tumor
size categories, reducing the magnitude of the increasing trend, particularly for tumors <1
cm. Substantially less impact was seen for the trends in larger tumors. Thus, changing
patterns in the completeness of tumor size data over time accounts for a portion of the
observed tumor size-specific trends, suggesting that analyses that do not account for this
change in reporting, such as the unadjusted tumor size data presented here as well as in
previously published data based on SEER, must be viewed with caution and that the impact
of diagnostic technology on the temporal trends in thyroid cancer is probably less than
previously suggested.
In addition, if screening or diagnostic technology were the sole cause of the temporal
increases, one would expect the increases to occur first and to the greatest extent among
subgroups of the population who have greater medical care utilization and access (e.g.,
women, persons of white race/ethnicity, and persons of higher SES) and later among other
subgroups, similar to what was observed for mammographic screening (39). Some of the
observed temporal patterns for thyroid cancer are consistent with a role of diagnostic
technology or screening, but most are not. While our study and others (2, 8, 11) observed
significant temporal increases in thyroid cancer among both men and women, the magnitude
of the increase in women is greater than in men in our study and others (8) but not in all
studies(11). In addition, the temporality of that increase is earlier in women than men in the
California data presented here but not in the SEER data as a whole (11). When examined by
race/ethnicity and as observed in our population, significant increases of a similar magnitude
and temporality are generally observed within and across all racial/ethnic groups in the
California data (32), whereas within the SEER data, the magnitude of the increase is similar
among whites and blacks but greater in those groups than other racial/ethnic groups (1, 8,
19). The observed patterns also differ by age. Similar to previously reported analyses using
SEER data (8, 11), in our study, the magnitude of the increased incidence was greater
among persons age 50 years and older, compared with younger men and women, although
the temporality was similar. Those persons age 65 years and older, who would be eligible
for Medicare coverage, experience rate increases similar to those age 50–64. Women age
20–34, who may have greater contact with the medical care system due to childbearing,
experience rate increases that are less than women age 35–49 or older. Contrary to a
previous report of SEER data that examined neighborhood SES based on county-level data
and found the increase in thyroid cancer to be greater among those in the highest 75% of
SES compared to the lowest 25% (21), our analysis of neighborhood SES, based on census
tract data (i.e., a more cohesive measure of neighborhood) suggests no differences in the
magnitude of the rate increase by SES, with the exception of a slightly higher rate of
increase of small tumors among those in the lower 60% of SES. Finally, we examined the
impact of acculturation on the trends in papillary thyroid cancer incidence. We observed no
differences by nativity, an individual-level proxy for acculturation. Hispanic and API
women have experienced significantly increased rates of thyroid cancer, regardless of
whether they are US-born or foreign-born; although the rate of increase for foreign-born API
women is small. For men, among whom thyroid cancer is less common, the changes
generally do not reach statistical significance. For Hispanics and APIs, we also examined the
impact of residence in an ethnic enclave, a neighborhood-level proxy for acculturation. This
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composite variable is based on census data at the tract- and block-levels which combines
data on nativity, recent immigration, poverty, language proficiency, and linguistic isolation
(23). Residents of more dense ethnic enclaves would be less acculturated and less likely to
benefit from new diagnostic technology. As with nativity, the incidence of papillary thyroid
cancer increased to a similar degree at all levels of ethnicity density whether examined alone
or in conjunction with SES. Thus, as with patterns examined by tumor characteristics,
patterns by patient and contextual characteristics suggest that factors beyond changes in
diagnostic technology are likely to be responsible for a significant portion of the temporal
increase in thyroid cancer incidence. Such factors may include exposure to various types of
radiation (10, 16, 18, 40) or environmental endocrine disruptors (2, 16), consequences of the
obesity epidemic, or the effects on immune function of the increasingly sterile environment
in which we live today.
Several strengths and limitations of the current analysis should be noted. First, in 1988, the
World Health Organization made modifications to their histologic classification scheme for
thyroid cancer, resulting in tumors which would have previously been classified as follicular
to now be classified as follicular variants of papillary, and thus, be included in our papillary
group (2). While it is not known how long it took for this new standard to diffuse across all
California hospitals, our analyses start with cases diagnosed concurrently with this
classification change and show significant increases in both types of thyroid cancer in
women, where we had sufficient statistical power. Thus, it is unlikely that this change in
classification had a major impact on the trends reported here. Second, the large and diverse
California population, and our ability to look at the effects of SES and acculturation based
on our enhanced surveillance data (23, 40), provides a powerful resource for examining
trends not only at the individual and tumor level but also on the social/contextual level.
Nonetheless, despite our large US- and foreign-born Hispanic and API populations, we did
suffer from imprecision in some of our estimates due to small numbers of cases in some
subgroups, particularly among men. In addition, despite the use of our validated imputation
method for determining nativity, there is the possibility of misclassification (32, 33). We are
also aware that there is misclassification of Hispanic ethnicity in cancer registry records;
however, accuracy of ethnicity-reporting has improved over time and the relative bias when
calculating age-adjusted incidence rates is minimal (<1%) (41, 42). There also may be errors
associated with the inter- and post-censal annual population estimates; this is a particular
concern for the extrapolated post-2000 estimates (43). Finally, a major strength of our
analysis is the conduct of a sensitivity analysis to address the impact that the temporal trends
in unknown tumor size had on the tumor size-specific trends in thyroid cancer rates. This is
particularly important since it impacts the interpretation of the relative contribution of
diagnostic technology, versus other causes, in the observed temporal trends.
In summary, we found that papillary thyroid cancer rates continue to increase and while
there was some variation in the magnitude of the increasing trends, there were statistically
significant increases in just about every subgroup examined. We conclude that while
diagnostic technology may account for a moderate portion of this increase, it is likely that
widespread environmental or common population trends are responsible for a substantial
portion of the continuing increase in thyroid cancer incidence. Furthermore, it is likely that
no one factor alone accounts for the temporal increase but that multiple factors or
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interactions between host and environmental factors are involved. Further research that
directly addresses the causes of these temporal trends is critical.
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Figure 1. Average annual age-adjusted thyroid cancer incidence rates (per 100,000) in
California, by sex and histologic type
Papillary: solid line with diamonds; follicular: dashed line with squares; medullary: small
dashed line with triangles; anaplastic: dotted & dashed line with circles; “not otherwise
specified”: dotted line with squares. Annual percent change, 1988–2009 (unless otherwise
specified), for men and women, respectively: papillary: 1988–98 1.1 and 1998–09 5.4*, and
1988–01 3.8* and 2001–09 6.3*; follicular: 0.0 and 1.2*; medullary 0.4 and 1.0; anaplastic
−0.9 and 1.2; and “not otherwise specified” histology: 3.0* and 0.3. * denotes p<0.05.
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Figure 2.
Reduction in differences in average annual percent change by tumor size in females due to
optimal allocation of unknown tumor sizes.
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)
-
-
-
-
57
0.
16
 (0
.10
–0
.24
)
0.
24
 (0
.17
–0
.34
)
1.
54
 (0
.87
–2
.77
)
 
Q2
35
0.
13
 (0
.08
–0
.21
)
0.
11
 (0
.06
–0
.18
)
0.
86
 (0
.41
–1
.79
)
14
9
0.
32
 (0
.24
–0
.43
)
0.
61
 (0
.50
–0
.75
)
1.
89
 (1
.32
–2
.75
)
 
Q3
56
0.
08
 (0
.04
–0
.14
)
0.
29
 (0
.21
–0
.38
)
3.
78
 (1
.85
–8
.41
)
21
4
0.
50
 (0
.39
–0
.63
)
0.
83
 (0
.70
–0
.98
)
1.
67
 (1
.24
–2
.25
)
 
Q4
86
0.
22
 (0
.14
–0
.32
)
0.
28
 (0
.29
–0
.50
)
1.
79
 (1
.09
–2
.98
)
35
5
0.
80
 (0
.66
–0
.97
)
1.
48
 (1
.30
–1
.68
)
1.
85
 (1
.47
–2
.35
)
 
Q5
 (m
os
t d
en
se)
21
7
0.
62
 (0
.48
–0
.78
)
0.
91
 (0
.76
–1
.08
)
1.
47
 (1
.09
–1
.99
)
79
9
1.
91
 (1
.68
–2
.16
)
3.
17
 (2
.91
–3
.46
)
1.
66
 (1
.43
–1
.94
)
SE
S 
/ e
nc
la
ve
b
 
lo
w
 / 
m
os
t d
en
se
10
1
0.
61
 (0
.43
–0
.83
)
0.
83
 (0
.63
–1
.08
)
1.
37
 (0
.89
–2
.12
)
41
9
2.
05
 (1
.74
–2
.40
)
3.
13
 (2
.75
–3
.54
)
1.
53
 (1
.24
–1
.88
)
 
lo
w
 / 
le
ss
 d
en
se
82
0.
10
 (0
.07
–0
.14
)
0.
15
 (0
.11
–0
.19
)
1.
47
 (0
.91
–2
.44
)
37
5
0.
40
 (0
.33
–0
.48
)
0.
64
 (0
.56
–0
.73
)
1.
61
 (1
.29
–2
.01
)
 
hi
gh
 / 
m
os
t d
en
se
11
6
0.
67
 (0
.46
–0
.94
)
1.
02
 (0
.81
–1
.27
)
1.
53
 (1
.00
–2
.39
)
38
0
1.
74
 (1
.42
–2
.11
)
3.
26
 (2
.88
–3
.67
)
1.
88
 (1
.49
–2
.38
)
 
hi
gh
 / 
le
ss
 d
en
se
10
5
0.
14
 (0
.10
–0
.20
)
0.
29
 (0
.22
–0
.36
)
2.
02
 (1
.30
–3
.15
)
40
0
0.
53
 (0
.44
–0
.64
)
1.
07
 (0
.95
–1
.21
)
2.
02
 (1
.62
–2
.52
)
a
Le
as
t d
en
se
 =
 li
vi
ng
 in
 a
 c
en
su
s t
ra
ct
 w
ith
 a
 lo
w
er
 d
en
sit
y 
of
 p
eo
pl
e 
of
 th
e 
sa
m
e 
ra
ce
/e
th
ni
ci
ty
, s
ug
ge
sti
ng
 g
re
at
er
 a
cc
ul
tu
ra
tio
n 
at
 th
e 
in
di
vi
du
al
-le
ve
l; 
m
os
t d
en
se
 =
 li
vi
ng
 in
 a
 d
en
se
ly
 e
th
ni
c 
ce
ns
us
 tr
ac
t,
su
gg
es
tin
g 
le
ss
 a
cc
ul
tu
ra
tio
n.
b S
ES
: l
ow
 (Q
1–
Q3
), h
igh
 (Q
4–
Q5
); 
en
cla
ve
: le
ss 
de
ns
e (
Q1
–Q
4),
 m
os
t d
en
se 
(Q
5);
 lo
w/
mo
st 
de
ns
e i
mp
lie
s a
 lo
w 
SE
S, 
les
s a
cc
ult
ura
ted
 liv
ing
 co
nte
xt;
 hi
gh
/le
ss 
de
ns
e i
mp
lie
s a
 hi
gh
 SE
S, 
mo
re
ac
cu
ltu
ra
te
d 
liv
in
g 
co
nt
ex
t..
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